ASX Share rice
Fri 07 Aug 2020 - 01:16:am (Sydney)

CYP Share Price

CYNATA THERAPEUTICS LIMITEDCYPPharmaceuticals, Biotechnology & Life Sciences

CYP Company Information

Name:

Cynata Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

62 Lygon Street Carlton VIC Australia 3053

Phone:

61 3 9824 5254

MD, CEO & Exec. Director:

Dr. Ross Alexander MacDonald Ph.D.

Chief Operating Officer:

Dr. Kilian Kelly

Company Sec.:

Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD

VP of Alliance Management:

Dr. Suzanne Lipe

Company Overview:

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.

CYP Share Price Information

Shares Issued:

117.12M

Market Capitalisation:

$75.54M

Revenue (TTM):

$4.45M

Revenue Per Share (TTM):

$0.04

Earnings per Share:

$-0.085

Profit Margin:

-1.807

Operating Margin (TTM):

$-1.86

Return On Assets (TTM):

$-0.39

Return On Equity (TTM):

$-0.64

Quarterly Revenue Growth (YOY):

2.4

Gross Profit(TTM):

$1.31M

Diluted Earnings Per Share (TTM):

$-0.079

CYP CashFlow Statement

CashFlow Date:

2019-06-30

Change To Liabilities:

$533.62K

Net Income:

$-8,472,146

Total Cash From Operating Activities:

$-6,759,077

Depreciation:

$279.97K

Change To Account Receivables:

$40.67K

Sale Purchase Of Stock:

$-75,514

Capital Expenditures:

$0

CYP Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-8,472,146

Net Income:

$-8,472,146

Gross Profit:

$1.31M

Operating Income:

$-10,061,130

Other Operating Expenses:

$2.28M

Total Revenue:

$1.31M

Total Operating Expenses:

$10.06M

CYP Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$3.25M

Total Liabilities:

$1.28M

Total Stockholder Equity:

$10.97M

Other Current Liabilities:

$41.30K

Total Assets:

$12.25M

Common Stock:

$47.99M

Other Current Assets:

$3.57K

Retained Earnings:

$-41,522,356

Other Assets:

$1.67M

Cash:

$6.98M

Total Current Liabilities:

$1.28M

Net Tangible Assets:

$7.72M

Total Current Assets:

$7.33M

Net Receivables:

$63.48K

Short-Term Investments:

$4.92M

Accounts Payable:

$790.96K

Non Currrent Assets (Other):

$4.92M

Short-Term Investments:

$4.92

Non Current Liabilities Total:

$0

CYP Share Price History

CYP News

18 Jun, 2020
Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to report important progress towards the commencement of recruitment in the Phase 3 clinical trial of CYP-004, its Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis. This trial is sponsored by the University of Sydney, and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant.
08 May, 2020
Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated guidance on its wider clinical development pipeline.
17 Apr, 2020
Cynata Therapeutics Limited (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus™ mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).1 The AJRCCM, commonly known as “The Blue Journal”, is widely regarded as the foremost peer-reviewed journal in the field of respiratory and critical care medicine. The study was conducted in 14 sheep with severe ARDS supported by extracorporeal membrane oxygenation (ECMO), which were given an endobronchial infusion of either Cymerus MSCs (n=7) or placebo (n=7).
11 Mar, 2020
MELBOURNE, Australia, March 11, 2020 -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce.
14 Jan, 2020
MELBOURNE, Jan. 14, 2020 -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has.
05 Dec, 2019
MELBOURNE, Australia, Dec. 05, 2019 -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received.
25 Nov, 2019
MELBOURNE, Australia, Nov. 25, 2019 -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has filed a.
04 Oct, 2019
Cynata Therapeutics Limited (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to provide an update on start-up activities of a Phase 2 clinical trial to evaluate Cynata’s Cymerus™ mesenchymal stem cells (MSCs) as a treatment for osteoarthritis, following the signing of an agreement with the University of Sydney.
17 Sep, 2019
MELBOURNE, Australia, Sept. 17, 2019 -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce.